Bleomycin sulfate is a glycopeptide-derived chemotherapeutic agent used primarily to treat cancers, including Hodgkin’s lymphoma, testicular cancer, and squamous cell carcinomas. Key details:
Mechanism: Induces DNA strand breaks via free radical formation, blocking cancer cell replication.
Administration: Intravenous or intramuscular injection; often combined with other chemotherapies.
Key Use: Critical in curative regimens (e.g., testicular cancer with cisplatin/etoposide).
Side Effects: Pulmonary toxicity (fibrosis) in 10-20% of patients, dose-dependent; skin hyperpigmentation.
Limitations: Cumulative lung damage risk mandates strict dose monitoring.
Production: Derived from Streptomyces verticillus; stabilized as sulfate salt for clinical use.
Research: Investigated in novel delivery systems (e.g., electrochemotherapy) to reduce toxicity.
Extended Summary
Bleomycin sulfate is a sulfur-containing glycopeptide antibiotic isolated from the bacterium Streptomyces verticillus. As a cytotoxic agent, it disrupts DNA synthesis by binding to Fe²⁺ ions, generating reactive oxygen species (ROS) that cleave DNA strands. Clinically, it is administered via injection and is integral to combination therapies, such as BEP regimen (bleomycin, etoposide, cisplatin) for testicular cancer.
While effective, its use is constrained by pulmonary fibrosis, a potentially fatal side effect linked to cumulative doses exceeding 400,000 IU. Patients undergo regular pulmonary function tests during treatment. To mitigate toxicity, research focuses on localized delivery methods (e.g., intralesional injection for warts) and biomarkers to predict susceptibility.
Bleomycin remains irreplaceable in certain cancers due to its unique mechanism, but alternatives like immunotherapy are being explored for long-term safety.
China
